Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 4/20 | 0.73 |
| ▸ | CYP19A1 | P11511 | 9/20 | 0.71 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.71 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6826664 | 0.85 | MIF (0.70) | MIFCYP19A1ALDH1A1LMNAMAPT | |
| SCHEMBL6827732 | 0.85 | MIF (1.00) | MIFCYP19A1CYP11B2CYP11B1ALDH1A1 | |
| SCHEMBL6827735 | 0.85 | MIF (1.00) | MIFCYP19A1CYP11B2CYP11B1ALDH1A1 | |
| SCHEMBL4226034 | 0.83 | CYP19A1 (1.00) | MIFCYP19A1CYP11B2CYP11B1 | |
| SCHEMBL4226031 | 0.83 | CYP19A1 (1.00) | MIFCYP19A1CYP11B2CYP11B1 | |
| SCHEMBL4226036 | 0.83 | CYP19A1 (1.00) | MIFCYP19A1CYP11B2CYP11B1 | |
| Hydrochloric Acid SCHEMBL4222413 | 0.82 | CYP19A1 (0.97) | MIFCYP19A1CYP11B2CYP11B1 | |
| Hydrochloric Acid SCHEMBL4231776 | 0.82 | CYP19A1 (0.97) | MIFCYP19A1CYP11B2CYP11B1 | |
| Hydrochloric Acid SCHEMBL4222419 | 0.82 | CYP19A1 (0.97) | MIFCYP19A1CYP11B2CYP11B1 | |
| SCHEMBL6822394 | 0.79 | MIF (0.85) | MIFCYP19A1CYP11B2CYP11B1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071195-B2 | Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2006-07-04 | — | — | US | disclosed |
| US-20060052388-A1 | Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders | DAX SCOTT L | 2006-03-09 | — | — | US | disclosed |
| EP-1493742-A1 | Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2005-01-05 | — | — | EP | disclosed |
| US-20020115715-A1 | Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders | DAX SCOTT L (US) | 2002-08-22 | — | — | US | disclosed |
| EP-1202986-A1 | AMINE AND AMIDE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y Y5 RECEPTOR USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2002-05-08 | — | — | EP | disclosed |
| US-6380224-B1 | FOR THERAPY OF EATING DISORDERS, OBESITY, BULIMIA NERVOSA, DIABETES, MEMORY LOSS, EPILEPTIC SEIZURES, MIGRAINE, SLEEP DISTURBANCES, PAIN, SEXUAL/REPRODUCTIVE DISORDERS, DEPRESSION AND ANXIETY | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-04-30 | — | — | US | disclosed |
| EP-1076644-A1 | N-SUBSTITUTED AMINOTETRALINS AS LIGANDS FOR THE NEUROPEPTIDE Y Y5 RECEPTOR USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2001-02-21 | — | — | EP | disclosed |
| WO-2001009120-A1 | AMINE AND AMIDE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y Y5 RECEPTOR USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-02-08 | — | — | WO | disclosed |
| US-6140354-A | FOR TREATMENT OF DISORDERS OR DISEASE STATES CAUSED BY EATING DISORDERS, OBESITY, BULIMIA NERVOSA, DIABETES, HYPERTENSION, MEMORY LOSS, EPILEPTIC SEIZURES, MIGRAINE, SLEEP DISTURBANCES, PAIN, SEXUAL/REPRODUCTIVE DISORDERS, DEPRESSION | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2000-10-31 | — | — | US | disclosed |
| WO-1999055667-A1 | N-SUBSTITUTED AMINOTETRALINS AS LIGANDS FOR THE NEUROPEPTIDE Y Y5 RECEPTOR USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 1999-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052388-A1 | Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders | NPY5R, NPY1R, NPY2R | MIF 4705/4885CYP19A1 468/4885CYP11B2 1872/4885 |
| US-20020115715-A1 | Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders | NPY5R, NPY1R, NPY2R | MIF 4702/4885CYP19A1 460/4885CYP11B2 1746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.